GlaxoSmithKline plans to strengthen its China R&D efforts, using collaborations to develop new neurological treatments. The research update came from GSK’s Min Li, PhD, who holds the dual titles of Global Head of Neurosciences and General Manager of R&D China. Established in 2007, GSK’s Shanghai R&D Center focuses on neurology. “In the field of neurological diseases, we are very much committed to neurodegeneration and neuroexcitation,” said Dr. Li. So far, GSK has established partnerships with scientists at four China universities.
